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Abstract 
Positron emission tomography (PET) using [18F]-fluoro-2’-deoxy-D-glucose (FDG) has an added 
value in the clinical management of patients with colorectal carcinoma (CRC). This includes restaging 
patients before surgical resection or local recurrence of liver metastases, assessment whether residual 
lesions are scar or recurrence and in pinpointing recurrence in case of unexplained increase in serum 
levels of carcinoembryonic antigen. 
At present, there is an increasing interest in new roles for FDG-PET, especially for 
characterisation of lesions, for prognosis and response prediction and for early evaluation of treatment 
response to commenced therapy. FDG-PET may lead to better selection of patients for different 
therapeutic options or to early individual adjustment of current treatment.  
This systematic review aims to provide an up-to-date overview of literature on the current and 
potential value of FDG-PET in CRC patients by addressing staging and recurrence detection, 
prognosis and response prediction and evaluation of preoperative (chemo)radiotherapy for primary 
rectal carcinoma, ablative treatment for unresectable liver metastases and chemotherapy for advanced 
CRC. 
 
Keywords: Positron-Emission Tomography, Colorectal Neoplasms, Fluorodeoxyglucose F18, 
management, therapy, prognostic stratification, response evaluation  
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Introduction 
Colorectal cancer (CRC) is the third most common malignancy and third leading cause of cancer-
related deaths in the United States. Even though the annual age-adjusted incidence rates and death 
rates are slowly declining in the last two decades, it remains a large health problem worldwide.1 
According to the National Cancer Institute1,2, the age-adjusted incidence rate in the United States 
(2001-2005) is 50.6 per 100,000 per year, with a cancer-related death rate of 18.8 per 100,000 per year 
and an overall 5-year survival rate of 64.4%. Approximately 5.3% of people will develop CRC during 
their lives and it is estimated that in 2008, 148,810 people were diagnosed with and 49,960 people 
died from CRC in the United States. 
At time of diagnosis, approximately 40% of CRC is confined to the primary site, 36% has spread 
locoregionally and 19% of patients are suffering from metastasised disease (for 5% in this registration 
the stage was unknown).1,2 Progress has been made in improvement of patient prognosis with the 
introduction of hepatic resection for treatment of isolated liver metastasis and with the development of 
effective chemotherapeutic and targeted agents.3,4 
Positron emission combined with computed tomography (PET/CT) with [18F]-fluoro-2’-deoxy-D-
glucose (FDG) has proven a useful diagnostic modality in different phases of CRC management. This 
comprehensive review discusses the current and potential future applications of FDG-PET in 
management decisions of patients with CRC. The literature is systematically reviewed on the 
(potential) role of FDG-PET in changing individual CRC patient management by addressing (i) the 
impact of FDG-PET on staging disease and detection of recurrence on individual management, (ii) the 
prediction of individual patient prognosis and therapy response, and (iii) the evaluation of treatment 
response. 
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Search strategy and selection criteria of literature 
References for this review were identified by systematic searches in PubMed, EMBASE (OvidSP), 
MEDLINE (OvidSP) and the Cochrane Library up to December 31, 2008. The strategy of Mijnhout et 
al.5 was adapted for our research question. The construct of the query was: “(PET OR PET/CT) AND 
colorectal AND cancer”, using medical subject headings, synonyms and truncations for all three 
building blocks of the search question (table 1). 
Only articles in English were included. A total of 1595 articles were retrieved and screened. 
Case-reports, small series (<15 patients), research by questionnaires, reviews, reports from meetings, 
abstracts of poster presentations, editorial comments or letters-to-the editor were excluded. Papers on 
disease (re)staging or recurrence detection which failed to describe the implications for clinical 
management or without verification of the results by histology or follow-up were excluded. Papers on 
treatment response without fixed outcome-parameters (e.g. histological or morphological response, 
patient survival) were excluded from further analysis. PET-tracers other than FDG were excluded. 
Results of the search strategy were supplemented by the references from included articles. In total 86 
articles were considered suitable for further discussion in this review. 
When considered appropriate, results have been pooled using fixed effects modelling, by 
weighting effect magnitudes (i.e. fraction management change) by their inverse variance. For 
calculation of the variance and confidence intervals of proportions the beta-distribution has been used 
since the commonly used asymptotic normal approximation only holds true for observed frequencies 
of five and larger.6 It should be noted, however, that the variation of results of individual papers is 
largely attributable to heterogeneity of the study populations. 
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1 Impact of FDG-PET on individual management in staging disease and 
detection of recurrence 
Many articles address the impact of FDG-PET during initial staging of primary CRC or in detection of 
recurrence. Recurrence of CRC can be suspected due to several findings during routine clinical follow-
up: abnormalities on morphological imaging and rise of the serum tumour-marker carcinoembryonic 
antigen (CEA). FDG-PET may have a pivotal role in patient management specifically in case of 
equivocal radiological studies, unexplained CEA rise or determination of resectability of local 
recurrence or colorectal liver metastases. 
 
1.1 Influence of staging primary CRC by FDG-PET on individual management 
In staging of primary rectal cancer, FDG-PET may influence on management in 12%7 to 27%8. Heriot 
et al.9 showed in 46 patients with histology proven stage II-IV rectal cancer that the use of FDG-PET 
after routine staging by abdominal CT and pelvic MRI and/or transrectal endo-ultrasonography 
(TREUS) before neoadjuvant therapy changed previously proposed management in 17% of patients. 
Of these eight cases, surgery was cancelled in six cases due to identification of metastatic disease and 
in two the neoadjuvant radiotherapy field was altered to include common iliac lymphadenopathy as 
identified by PET. Gearhart et al.8 prospectively compared abdominal spiral CT and FDG-PET/CT 
after TREUS or pelvic MRI in 37 patients with previously untreated biopsy proven adenocarcinoma of 
the rectum and found discordant findings in 38%, leading to changes in the previously proposed 
treatment plan in 27%. Of these 10 cases, in five patients additional lymph node metastases were 
found not detected by CT alone leading to neoadjuvant treatment or extension of the radiotherapy 
field. In two cases, CT-positive lymph nodes proved negative on PET leading to cancellation of 
neoadjuvant treatment or radiotherapy. In three additional cases more extensive surgical resection was 
performed. Bassi et al.10 showed that additional staging by FDG-PET/CT in 25 T3-4 rectal cancer 
patients who were candidates for neoadjuvant chemoradiotherapy (CRT) prior to surgery led to 
Page 6 of 42 
 
treatment changes in 16%. FDG-PET identified unknown nodal involvement and undiagnosed liver 
metastases. Another study in 83 patients performed by Davey et al.7 showed that staging FDG-
PET/CT could lead to management changes in 12% of primary rectal cancer patients. Of these 10 
cases, surgery was cancelled in six patients due to unexpected metastases, in three neoadjuvant CRT 
was considered necessary due to identification of pelvic nodal spread and in one patient neoadjuvant 
CRT was cancelled because iliac lymph node metastases on CT appeared to be false-positive. 
In staging of primary CRC, FDG-PET may influence on management in 2%11-27%12. 
Kantorova et al.13 found a change of treatment in 16% of 38 patients with histologically proven 
primary CRC which were prospectively staged by conventional imaging and FDG-PET (8% treatment 
modality change, 13% change in range of surgery). Park et al.12 studied 100 patients with primary 
CRC (45 colon and 55 rectum carcinoma: 3 stage I, 23 stage II, 25 stage III, 49 stage IV) planned for 
surgery with FDG-PET/CT who had increased CEA or showed equivocal signs of metastases on CT. 
In 27% of the patients, proposed treatment plan was modified: nine had treatment modality changes, 
10 received more extensive surgery and in 8 unnecessary procedures could be avoided. The reason for 
a large proportion of patients in whom management changed might be that they only included patients 
with a relatively high likelihood of metastasised disease due to equivocal radiological findings or 
increased CEA levels. Veit-Haibach et al.14 performed FDG-PET/CT in 47 patients with suspicious 
lesions at colonoscopy (50 sites: 13 rectum and 37 colon cancer). They found that FDG-PET/CT 
compared to CT alone led to management changes in 9% of the patients. Another study, by Llamas-
Elvira15, showed that using FDG-PET/CT next to CT changed management in 12% of the 104 patients 
with histology proven CRC (56 rectum and 44 colon cancer) referred for surgery. In seven cases 
surgery was cancelled for extensive disease not detected by CT and in five the therapeutic approach 
was altered. In contrast, Furukawa et al.11 showed no impact of FDG-PET/CT over whole-body CT 
alone, as PET/CT only changed management in 1 of 44 patients (2%) with histologically proven 
primary CRC (38 rectum carcinoma). They attributed discordance with other authors to the less 
advanced disease stage in their patient series.  
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Pooling the data of the four studies on rectal carcinoma leads to a weighted mean change in 
management of 15.7% (95% confidence interval: 10.8%-21.7%), as shown in figure 1. For the studies 
with both colon and rectal carcinoma (CRC) the weighted mean change in management is 10.7% (95% 
confidence interval: 7.6%-14.5%). Apparently due to the limited influence of FDG-PET on 
management in these patients, the latest editions of the European Society for Medical Oncology 
(ESMO) guidelines for rectal cancer16 or CRC17 do not recommend to use this technique routinely for 
staging primary disease They do however note that for staging in advanced CRC18, FDG-PET can 
have a role. 
 
1.2 Influence of FDG-PET in suspected recurrence on individual management 
Many studies have been performed to investigate whether FDG-PET changes management in patients 
in whom recurrent CRC was expected based on equivocal lesions on conventional diagnostic follow-
up, rising CEA levels with normal radiologic findings or during restaging before surgical treatment of 
local recurrence or metastases. 
 
1.2.1 Equivocal radiologic findings suggestive for recurrence 
After radiotherapy or surgery of the primary tumour, most patients develop a region of scar tissue in 
the surgical bed. These changes complicate the detection of local recurrence by ultrasound, CT or 
MRI. FDG-PET can distinguish metabolic active disease (tumour) from less active disease (scar 
tissue). An example is shown in figure 2. 
Of the 35 patients with a history of resected primary CRC described by Beets et al.19, eight 
cases were included for presacral masses with uncertain CT findings. FDG-PET correctly classified 
them as recurrence in 5 cases (62.5%) causing change in management in these patients. In the series of 
Simo et al.20, patient management was altered in 14 of 31 patients (45%) with inconclusive imaging 
during follow-up after surgical resection of primary CRC. In all patients treatment changed from local 
therapy to systemic treatment for disseminated disease. Scott et al.21 described 93 patients with 
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residual structural after surgery for primary CRC suggestive of recurrence. Treatment changed in 66% 
of these patients. 
One study22 examined the influence of FDG-PET during routine follow-up after a history of 
CRC when there was no sign of recurrence as physical examination, CT, MRI and CEA were all 
normal. FDG-PET changed individual management in only 2 of 31 cases (6%). The first was an 
omental metastasis and the second was a false positive PET causing unnecessary laparotomy. 
Therefore, follow-up of CRC by FDG-PET without any signs pointing to recurrence seems to be of 
limited value. 
 
1.2.2 Unexplained rise in CEA 
When serum CEA levels rise during postoperative surveillance in asymptomatic patients and history 
taking, physical examination and imaging do not lead to a distinct cause, treatment decisions are 
difficult to be made. With the aid of FDG-PET, localisation of the source of increased serum CEA 
levels may lead to a change in management in the majority of patients. 
FDG-PET in patients with a history of CRC and CEA rise with normal (n=31) or equivocal 
(n=19) findings on conventional work-up (including abdominal CT and chest X-ray or CT) detected 
recurrent disease in 68% of patients in the study of Flamen et al.23, thereby changing management 
from observation to start of a new treatment (curative surgery for resectable disease or finding of non-
resectable disease). Of the 56 lesions, 20% were local recurrences, 27% liver metastases, 9% lung 
metastases, 36% other abdominal lesions and 9% were non-pulmonary extra-abdominal lesions. In the 
subgroup of eight patients included in an earlier study by Flamen et al.24 with a rising CEA level but 
negative findings on morphologic imaging, PET led to change in management in 3 (37.5%), due to 
detection of one local recurrence, one liver metastasis and one lymph node metastasis. Valk et al.25 
described 18 patients with a rise of CEA without abnormal findings on abdominal CT-scanning. Of 
these, 12 patients had detectable disease by FDG-PET (67%), which was subsequently histologically 
confirmed to be recurrent CRC. Simo et al.20 described a subset of 58 patients with rise of CEA with 
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normal findings on conventional imaging. With FDG-PET, they found the cause in 34 patients (59%), 
resulting in change of management. Of these, 18 could be treated with curative surgery, whereas the 
remaining 16 were treated with systemic therapy. Even-Sapir et al.26 mentioned 16 cases with occult 
rising of CEA in which 13 (81%) tumour recurrences were detected. Of these patients nine were 
treated with chemotherapy and four with surgery. Only one patient had a negative PET despite an 
intraluminal recurrence at repeat colonoscopy. Shen et al.27 reported that PET had influence on 
individual management in 41 of 50 patients (82%) with suspicion of recurrent CRC based on 
asymptomatically elevated serum levels of CEA. 
 
1.2.3 Restaging for resectable local recurrence 
When local recurrence is confirmed, resectability of disease is assessed by restaging the patient. FDG-
PET can be useful by detecting distant disease, which makes surgery futile.  
In case of presumed resectable pelvic recurrence of rectal carcinoma, Faneyte et al.28 found 
management changes in 14% of 32 cases due to discrepant PET findings after conventional imaging. 
These five cases caused cancellation of surgery for extensive disease in one, less extensive surgery in 
three and surgery instead of palliative therapy in one. 
Flamen et al.24 described a subset of 23 patients with recurrent locoregional CRC which was 
presumed resectable based on clinical and radiological findings. In eight of these patients (35%) 
management was altered due to unexpected findings of additional tumour sites in five and the 
exclusion of disease in three patients. Valk et al.25 described a subgroup of 78 patients with a history 
of CRC with local recurrence considered resectable based on conventional diagnostic workup. FDG-
PET showed additional lesions in 23 patients (29%) rendering these recurrences unresectable. In 
contrast, PET did not show any signs of recurrence in six patients, of whom two showed malignant 
local lesions during laparotomy. Kalff et al.29 asked the attending clinicians to assign a treatment plan 
to 102 consecutive patients with recurrent local CRC presumed being resectable based on 
conventional imaging. This treatment plan was then compared with that based on incremental 
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information supplied by FDG-PET. In 54 cases treatment plan was altered due to unexpected PET-
findings and in 6 more cases referring oncologists would not commit to a management plan without 
access to PET-information (59%). Of all these cases, one false positive result was due to a pelvic 
abscess and in four the extent of metastatic disease was underestimated by PET. 
 
1.2.4 Restaging for resectable liver metastases 
FDG-PET can be used to restage disease in case of presumed resectable liver metastases to confirm 
resectability in these patients and to avoid futile liver surgery. 
Wiering et al.30 performed a systematic review and a meta-analysis of 32 studies published up 
to 2003 concerning patients selected for surgical treatment for liver metastases. They found pooled 
sensitivity and specificity for FDG-PET to be 88.0% and 96.1% for hepatic lesions and 91.5% and 
95.4% for extra-hepatic lesions. Pooling results of CT-scanning resulted in 82.7%, 84.1% (hepatic 
lesions), 60.9% and 91.1% (extra-hepatic lesions), respectively, underlining the higher sensitivity of 
FDG-PET for extra-hepatic lesions as compared to CT. Detection of extra-hepatic lesions may lead to 
management changes such as a different surgical approach or cancellation of surgery for extensive 
disease and starting of palliative chemo(radio)therapy. They noted that only 18 of 32 studies 
mentioned the change in patient management due to FDG-PET findings, the pooled value being 32% 
(range: 20-58%). 
Our search query resulted in 25 papers19,20,24,31-52 in which FDG-PET was used in restaging 
patients prior to surgery for liver metastases (figure 3). Management changes were reported in 11%37 
to 70%20. The authors of the paper with lowest management change (11%)37 noted that in their 
population in only 5.5% of patients intra-abdominal unexpected extrahepatic metastases were present, 
a number which is exceptionally low. They attributed this to improvement of accuracy of conventional 
diagnostic imaging. The high percentage of management changes noted by Denecke et al.49 (52%) was 
possibly due to the fact that they included patients with recurrence after LASER induced 
thermotherapy of unresectable liver metastases. A high number of unexpected extrahepatic lesions was 
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found. In addition, when calculating management changes, 2 of 11 cases were included, in which 
false-positive FDG-PET results led to inadequate conclusions and unnecessary interventions. For Simo 
et al.20 the high proportion of management changes (7 of 10 patients who were restaged before liver 
surgery) might be due to inclusion of 3 cases in which changes were limited to surgical planning (use 
of RFA or resection of additional lesions). 
The pooled mean management change in these 1,060 patients is 22.3% (95% confidence interval: 
19.8%-24.9%,). An example of how FDG-PET can influence management in liver metastases is 
displayed in figure 4. The results of Scott et al.21 (management changes in 49% of 98 patients) were 
not used for calculation of pooled management change, since they included both patients with 
potentially resectable hepatic and pulmonary CRC metastases. It was not possible to derive how many 
of these had liver lesions only. 
The consequence of restaging these patients by FDG-PET prior to liver surgery is described in 2 
cohorts of in total 203 patients who were selected for hepatic surgery.53 Patients staged by FDG-PET 
(group A, n=100) were compared to patients staged by CT alone (group B, n=103). Although futile 
laparotomy ratios were similar for both groups (19.4% versus 28.0%, p=0.186), significantly less 
extrahepatic disease was seen during surgery in the cohort of patients staged by FDG-PET (1.9% 
versus 10%, p=0.017). Most of these futile laparotomies were due to too extensive hepatic disease, but 
no difference between both cohorts were seen (17.4% versus 17.0%, p=1.000). Pawlik et al.54 on the 
other hand did show in a retrospective analysis of 461 patients surgically treated for liver metastases in 
the same period, that the rate of unnecessary laparotomies was significantly lower in patients restaged 
by FDG-PET compared to patients who did not have FDG-PET (5.6% versus 12.4%, p=0.009). 
Fernandez et al.55 described improved overall survival in patient selected for surgery for liver 
metastases by FDG-PET. In their study, the outcome of 100 patients selected for resection of hepatic 
metastases by FDG-PET had better 5-year overall survival rates than in 19 reviewed similar studies 
(including 6,066 patients) not using functional imaging. Five year overall survival in this study was 
58.6% (95% CI 45.6%-71.6%), which was higher than in the 19 other studies (30%, ranging 12%-
41%). Strasberg et al.36 noted that in their series of 35 patients restaged by PET before liver surgery, 3-
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year overall survival was 77% and this proportion was higher than any of the 13 similar articles they 
reviewed that used conventional restaging (ranging 30%-58%). However, care must be taken to 
compare results with historic data, since the improvements in CT scans has led to stage migration and 
thus survival benefit.56 Wiering et al.53 found no differences in both overall survival (3-year: 57.1% 
versus 60.1%, p=0.678) and disease free survival (3-year: 29.9% versus 29.2%, p=0.656) between the 
group restaged by FDG-PET and the group without FDG-PET. They explain this discrepancy by 
stating that they used well-matched control group in contrast to the others who used a historical 
control group. The effect of FDG-PET on overall survival seemed lower than reported in these other 
studies. They concluded that tumour biology, resectability and chemotherapy response seem to be the 
major determinants of survival and that their results suggest that the intraoperative surgical approach 
to disease control and postoperative care in both groups were similar. 
It should be noted that previous chemotherapy lowers sensitivity of FDG-PET when restaging 
patients before liver surgery for liver metastases. Akhurst et al.57 stated that sensitivity of FDG-PET in 
the detection of colorectal metastases during preoperative staging was decreased in patients pre-treated 
by neoadjuvant chemotherapy due to downregulation of hexokinase activity (lesion detection 
sensitivity: 63% versus 77%). No lesions larger than 1.2 cm were missed in the untreated group, but 
lesions up to 3.2 cm were missed after neoadjuvant chemotherapy. Interpretation of FDG-PET data 
should be done with caution in the context of concomitant chemotherapy. In this respect both the 
specific cytostatic agent(s) prescribed as the timing of PET scanning after neoadjuvant treatment are of 
relevance. 
 
1.2.5 Overall effect on treatment decisions in suspected recurrence 
The remaining papers21,26,58-65 dealt with heterogeneous populations of patients in whom during follow-
up of CRC any recurrence or metastasis was suspected based on clinical findings, CEA increase or 
conventional diagnostic imaging (table 2). In these studies the detection ratio of local recurrence 
(sensitivity) by FDG-PET varied from 90% to 100%, which is higher compared to CT (71%-88%). 
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Specificity of PET and CT in these studies was similar (86%-92% for PET versus 85%-89% for CT). 
For hepatic metastases sensitivity and specificity for PET versus CT were 89%-100% versus 45%-
100% and 91%-100% versus 60%-100%, respectively. For extra-hepatic metastases sensitivity and 
specificity were 94%-100% versus 64%-74% and 40%-100% versus 50%-96% for PET versus CT, 
respectively. Management changes in these 10 paper varied from 6%-30%. Huebner et al.66 performed 
a meta-analysis of 11 similar articles up to 1999 and found a pooled management change in 29% (95% 
confidence interval: 25-34%). 
The consequence of PET-tailored management in follow-up of patients after curative resection of 
colonic or rectal cancer was investigated by Sobhani et al.67 They stratified and randomised 130 
patients in a group with a standardised follow-up consisting of history taking, physical examination, 
biomarker assays and conventional imaging (ultrasound, thorax X-ray, abdominal CT) and a group in 
which this follow-up included a whole body FDG-PET after 9 and 15 months. They found the time to 
recurrence-detection was significantly shorter in the FDG-PET arm (12.1 versus 15.4 months, p=0.01) 
associated with more curative resections of recurrences (65% versus 9.5%, p<0.01). 
The added value of fusing FDG-PET and CT was assessed by Fukunaga et al.68, who compared 
fused PET/CT with separate PET and CT in patients with suspected local recurrence after curative 
resection of rectal cancer. They reported improved accuracy of diagnosis of fused PET/CT over PET 
or CT alone of 93%, 79% (p=0.0138) and 88% (p=0.0156), respectively. Nakamoto et al.64 
investigated 63 patients with suspected recurrent CRC but failed to show a significant improvement of 
diagnostic accuracy of FDG-PET/CT (CT alone: 78%, FDG-PET alone: 79%, FDG-PET and CT: 84% 
and fused FDG-PET/CT: 92%, p=0.13). Even-Sapir et al.26 showed in 62 patients with suspected 
recurrence or metastases after rectal cancer and preoperative staging for rectal cancer, that the 
specificity of fused PET/CT is higher than PET alone (89% versus 74%, p<0.05) with similar 
sensitivity (96% versus 88%). 
 
It can be concluded that FDG-PET results in modification of individual patient management in 
situations where conventional diagnostic work-up shows equivocal findings in CRC patients (45%-
Page 14 of 42 
 
66%), in patients with unexplained rise in CEA (37.5%-82%), in preoperative restaging of resectable 
local recurrence (29%-59%) and assessment of patients before surgery for liver metastases (11%-
70%). Interpretation of FDG-PET-images for detection of metastases should be carried out with 
caution during or soon after administration of chemotherapy, since the sensitivity for detection of 
metastases is lower than normal. Use of FDG-PET in patients with a history of CRC without clinical, 
biochemical or radiological signs of recurrence, appears of limited additional value. 
The value of metabolic imaging next to morphologic imaging seems to have high sensitivity for 
local disease with similar specificity as CT. Especially in detection of extrahepatic metastases, the 
application of FDG-PET is superior to CT alone. In a population with suspected recurrence, 
management will change in about 6%-30% due to FDG-PET findings leading to earlier detection of 
recurrences and to more curative resections. Combined PET/CT is superior to PET alone in recurrence 
detection. 
 
2 Prognostic stratification and response prediction by PET 
2.1 Determination of prognosis by PET  
The use of (semi)quantitative parameters for tracer uptake before start of treatment, such as the mean 
standardised uptake value (SUVmean), maximum standardised uptake value (SUVmax) or parameters of 
FDG-metabolism in tumour lesions, can be related to overall patient outcome (prognosis). This might 
help in selecting the appropriate treatment for an individual patient (table 3). 
Calvo et al.69 performed a study in primary rectal cancer treated by neoadjuvant CRT (45-50.4 Gy 
combined with 5FU/FA or tegafur) followed by surgical resection showed that the 3-year overall 
survival ratio in patients with a (arbitrarily chosen) SUVmax of 6.0 or lower on baseline FDG-PET was 
significantly higher than for higher values for the SUVmax (92% versus 60%, p=0.04), see table 3. The 
abovementioned paper of Scott et al.21 showed the prognostic potential of FDG-PET in a subgroup of 
93 patients with residual structural lesions during follow-up of CRC after primary surgery. 
Significantly better 1-year progression free survival was found when no additional lesions were 
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detected by PET as compared to patients in whom PET showed additional lesions (60.5% versus 
36.2%, p=0.04). 
Most studies which used baseline PET to predict patient outcome used individuals with 
metastasised disease treated either with surgery or chemotherapy. Dimitrakopoulou-Strauss et al. 
published a paper70 on patients with metastatic CRC treated with second line FOLFOX (folinic acid / 
5FU / oxaliplatin). They used FDG SUVmean, fractal dimensions and pharmacokinetic rate constants 
combined in a discriminant analysis in 25 patients. SUVmean correctly classified 1-year overall survival 
in 67% and the pharmacokinetic parameters in 76%. Unfortunately, their discriminant functions with 
coefficients were not provided, which makes implementation of their model in different subsets of 
patients difficult. Our group used the FDG SUVmean in 152 patients with CRC metastases treated by 
resection or pyrimidine-based chemotherapy. The 76 patients with a SUVmean lower than 4.26 had a 
longer median overall survival than the rest of the patients (32 months versus 19 months, p=0.017).71 
Riedl et al.72 performed a similar experiment in surgically treated liver metastases and found overall 
survival benefit in subgroups of patients with lowest SUVmax for a range of cut-off values (table 3). 
Scott et al.21 showed prognostic ability of FDG-PET in another subgroup of 98 patients restaged 
before resection of presumable resectable hepatic and pulmonary metastases. In this group, significant 
better 1-year progression free survival was found when no additional lesions were detected by PET 
compared to patients in whom PET did show additional lesions (65.9% versus 39.2%, p=0.01). 
 
2.2 Prediction of response by PET 
The imaging of glucose uptake of CRC lesions before start of treatment might indicate which patients 
are more likely to respond to therapy. For patients that are less likely to respond to the opted treatment, 
a different therapeutic approach might be beneficial. For this purpose, baseline (semi)quantitative 
parameters of tracer uptake, such as the SUVmean are related to individual patient outcome (table 4). 
For primary rectal cancer treated with 50 Gy of neoadjuvant radiotherapy prior to surgery, Oku et 
al.73 found a negative correlation between the shrinkage rate on CT and the baseline SUVmean 
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measured by FDG-PET of the lesion (i.e. the larger the SUVmean prior to treatment the larger the 
treatment induced reduction in lesion size). However, this correlation was very weak and not 
significant (correlation coefficient: -0.162, p=0.326). They found that only follow-up SUVmean 
correlated with morphological changes and rationalised that a high SUV at follow-up indicated both a 
high SUVmean at baseline and a low reduction of uptake during treatment. 
Dimitrakopoulou-Strauss et al.74 published a paper on patients with metastatic CRC treated with 
second line FOLFOX. They showed by discriminant analysis that the pretreatment SUVmean correctly 
identified nonresponders (96% of 28 patients with progressive disease). The same limitations to 
implementation of their model apply as described in the previous paragraph. 
 
Functional imaging of lesions before start of treatment can identify patients with poor prognosis or 
who are less likely to respond to treatment. These patients might benefit from treatment-modification, 
when alternatives exist. Using a baseline FDG-PET, it appears feasible to stratify patients with 
different prognosis and possible resistance to treatment in CRC. So far, no prospective randomised 
controlled trials have been published using baseline FDG-PET for determination of individual 
treatment strategy. 
 
3 Treatment follow-up by PET-response evaluation 
After localised or during systemic treatment, tracer uptake in lesions can be monitored. Uptake during 
follow-up can be compared to baseline uptake, can be used to assess the effect of therapy and might be 
used as (early) prediction of treatment response or be related to patient survival for prognostic 
purposes. Thereby it might contribute to early change in management, if alternative treatment options 
are available. Response evaluation is most often performed by morphologic imaging according to 
RECIST (response evaluation criteria in solid tumours)75,76. In an era where new cytotoxic treatment is 
cytostatic rather than cytoreductive, metabolic changes may precede anatomical changes, PET-
imaging might aid in early response evaluation. 
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3.1 Response evaluation of radiotherapy in rectal cancer 
Engenhart et al.77 were the first to address the effect of irradiation on inoperable presacral recurrent 
rectal carcinoma in 21 patients. They noticed a small but significant decrease in FDG uptake during 
radiotherapy (2.3 to 1.6 uptake-units after 6 months, p=0.002). Oku et al73 described a significant 
negative (r=-0.383, p=0.0140) correlation between shrinkage rate on CT (fractional decrease in tumour 
axial diameter) and FDG SUV ratio (fraction remaining SUV of follow-up compared to baseline) after 
50 Gy of radiotherapy to primary rectal cancer in 40 patients.  
Two studies compare TNM tumour (T-)stage, relating baseline TREUS T-stage with follow-
up histological T-stage. In 25 patients with local invasive primary rectal cancer treated with 
neoadjuvant CRT prior to surgery, Calvo et al.69 described a significant difference in SUVmax-
reduction (ΔSUVmax) between patients with reduction in T-stage compared to non-responders (-3.3 
versus -1.9 SUV-units, p=0.03). Denecke et al.78 showed that a cut-off for ΔSUVmax of -36% was able 
to separate responders from non-responders: 76% of FDG-PET responders demonstrated T-
downstaging and 100% of FDG-PET non-responders did not show T-downstaging and (p=0.002) in 23 
patients with advanced rectal carcinoma treated with neoadjuvant CRT in combination with 
hyperthermia. Results of PET were superior to CT or MRI in response prediction. 
Many studies compared visual FDG-PET response79-81, ΔSUVmax79,82-89, ΔSUVmean90,91, SUV-
ratio92 and δTLG (change in total lesion glycolysis: the product of metabolic volume and SUV) at 
different intervals after radiotherapy, varying from 12 days90 up to 7 weeks79,81 and all found a 
significant relation with semiquantitative histological response (table 5). Depending on response 
criteria, predictive values of FDG-PET response (NPV) ranged from 83%91 to 100%88 and predictive 
values of FDG-PET non-response (PPV) varied from 77%87 to 100%84,90. The worst results were found 
by Engenhart et al.77 and Melton et al.88 who used rigorous criteria for definition of treatment response 
(complete SUV normalisation77 and ΔSUVmax ≥ -70% determined by ROC analysis88) and found a 
PPV of 20% and 58% respectively, which means 42%-80% of the patients without response on FDG-
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PET, clinically did show local control77 or regression score during histopathological examination88. 
Kristiansen et al.81 on the other hand used a very strict criterion for pathological response (defined as 
no histological detectable residual carcinoma) and therefore 40% false FDG-PET therapy responses 
were found (accuracy 53%). This confirmed the data of Guillem et al.93, who found an accuracy of 
60% for PET to define the extent of pathological response. Rosenberg et al.91 attributed their low 
predictive value of non-response FDG-PET (PPV: 64%) to be due to influx of inflammatory cells. 
The prognostic value of the metabolic response of rectal cancer to neoadjuvant CRT has been 
described in a few studies.80,85 Guillem et al.85 dichotomised FDG-PET results in responders and non-
responders in 15 patients with locally advanced primary rectal cancer treated by preoperative CRT. 
Responders were defined as those with only focal or diffuse FDG uptake with a maximum SUVmax of 
1.4 on the follow-up PET-scan. They showed higher median overall survival (>54 weeks versus 39 
weeks, p=0.08) and higher median disease-free survival (>54 weeks versus 26 weeks, p=0.02) of 
responders compared to non-responders. The corresponding 5-year overall survival percentages were 
91% versus 70% (p=0.024) and 5-year disease free survival percentages were 81% versus 62% 
(p=0.003). In another study in 34 patients treated with neoadjuvant CRT before curative surgery, 
visual PET response was categorised into complete remission, partial remission and stable or 
progressive disease before results of pathology were available. This PET-based response stratification 
showed 3-year overall survival percentages of 100%, 79% and 0% respectively (p<0.0001) and 3-year 
disease free survival percentages of 100%, 47% and 0% respectively (p<0.0001).80 
A drawback of post-radiotherapy FDG-PET is the radiation-induced inflammation.94 This 
causes influx and activation of macrophages, neutrophils, fibroblasts and granulation tissue, that can 
accumulate approximately 25% of FDG uptake.95 On the other hand direct effect of radiation may 
induce tumour cell dormancy (“stunning”) which mimics glucose metabolic response.84 Siegel et al.89 
saw metabolic response (ΔSUVmax= -39.3%) after short course radiotherapy (25 Gy in 5 days) at day 9 
but could not correlate these results to histopathology (negligible morphological response) which 
might partly be explained by the latter effect or due to the fact that surgery is performed immediately 
after radiotherapy in contrast to CRT where surgery is postponed 6 weeks. 
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FDG-PET allows prediction of pathological response in patients treated by neoadjuvant CRT. 
Moreover it seems able to predict overall and disease free survival after surgery with curative intent. 
However, the clinical consequences remain unclear. It does not seem possible to select patients who 
have no advantage of surgery after neoadjuvant treatment. It seems possible to demonstrate functional 
response after short-course radiotherapy89 but there are no data that shortening of neoadjuvant 
treatment prior to surgery (i.e. when no histopathological data is available) might benefit the subgroup 
of patients with early PET-response to CRT or that escalation of chemoradiation (e.g. increasing the 
radiation dose, adding regional hyperthermia, decision for intraoperative radiation) might benefit the 
subgroup of patients with no PET-response. Discrimination of responders to neoadjuvant 
chemoradiation from non-responders could also be used for preoperative selection for individualised 
surgery. This could include sphincter-saving surgery in deep-seated tumours, less aggressive treatment 
in limited disease or planning of intraoperative radiation therapy. However, no studies provide 
definitive evidence. Apart from selection for individualised surgery, FDG-PET-response might 
theoretically help to decide which patient benefits from adjuvant chemotherapy after surgery, but no 
studies concerning this have been published either, nor compared this to the use of histopathological 
data obtained during surgery. 
 
3.2 Effect of local ablative therapy of liver metastases 
Qualitative assessment of FDG-PET imaging after cryosurgical or radiofrequency ablation of 
unresectable liver metastases has advantages over conventional imaging such as CT, MRI and 
ultrasonography since latter techniques do not easily identify treatment failures at an early stage. This 
is due to hyperechogenicity and rim-like contrast enhancement caused by regional hyperperfusion, 
resembling residual tumour96. The predictive value of a negative FDG-PET 3 weeks after local 
ablative therapy varied from 97%97 to 100%98 and of a positive PET from 80%98 to 86%97 in two 
studies treating 81 patients with 237 hepatic lesions. The lower positive predictive value is caused by 
false-positive results due to liver abscesses occurring after local ablative therapy (table 6). 
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Donckier et al.99 compared the predictive value of FDG-PET 1 week and 3 months after 
radiofrequency ablation of unresectable liver metastases. They found that an early negative PET (after 
1 week) is less suitable for determining the disease free status as compared to a late negative PET 
(NPV: 54% versus 75%) whereas both early and late positive PET show 100% (positive) predictive 
value for residual tumour or recurrence. Apparently the optimal timeframe to judge the effect of local 
ablative therapy is somewhere between 1 weeks and three months after surgery. 
Denecke et al.49 used FDG-PET after LASER induced thermotherapy ablation (LITT) of 
unresectable liver metastases when tumour progression was suspected on MRI or obscure rising serum 
levels of CEA. Standardised visual interpretation of the images based on consensus of two blinded 
nuclear medicine physicians led to a negative predictive value of PET of 96% and a positive predictive 
value of 97%. Using the SUVmax they found a negative predictive value of 96% and a positive 
predictive value of 93%. They concluded that FDG-PET is a promising tool for assessment of local 
control and whole-body restaging in patients with clinical suspicion of tumour progression after local 
ablative treatment for liver metastases. Timing of follow-up though was highly variable in this study, 
since FDG-PET was performed only when tumour progression was suspected and 11% of follow-up 
scans were performed immediately (1-3 days post-LITT), 50% at short term (within 6 months post-
LITT) and 39% after more than 6 months post-LITT.  
FDG-PET seems a promising modality to select patients with incomplete tumour ablation or 
with early relapse after local ablative treatment for unresectable liver metastases. Assessment of local 
control by FDG-PET three weeks after local ablative treatment seems advisable. 
 
3.3 Evaluation of response to chemotherapy 
Depending on the drug and regimen, cytotoxic treatment has a clear influence on CRC 
adenocarcinoma cell lines. Oxaliplatin, 5FU and irinotecan cause decreased FDG uptake after 72 hours 
due to decrease in glucose transport, a decrease in hexokinase activity.100 This effect can be monitored 
by FDG-PET during systemic treatment of liver metastases. 
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Findlay et al.101 were the first to report the effect of 5FU with or without interferon-α 
chemotherapy on liver metastases larger than 3 centimetres in diameter with FDG-PET. They used 
morphological CT response as outcome measure and found that a reduction in tumour to normal liver 
(T:L) ratio of tissue activity concentrations of 15% or more has a sensitivity of 100% with a specificity 
of 75% to predict morphological response. They noted that patients with an increase in T:L 1-2 weeks 
subsequently had a reduction in T:L at 4-5 weeks, suggesting that this “flare” phenomenon is caused 
by infiltration of macrophages as response to tumour cell kill (i.e. early inflammatory reaction). 
The two abovementioned papers by Dimitrakopoulou-Strauss et al.70,74 also evaluated 
treatment response by including follow-up FDG-PET in 28 and 25 patients treated with second line 
FOLFOX. The prognostic value of the metabolic response of liver metastases to chemotherapy is 
described in three papers.70,102,103 Dimitrakopoulou-Strauss et al.70 showed prognostic aspects of 
dynamic FDG-PET response in 25 patients treated with second line FOLFOX. Discriminant analysis 
based on SUVmean correctly classified overall survival in 69% of the patients and based on 2-
compartment rate constants, vascular fraction and fractal dimensions correctly classified overall 
survival in 78% of the patients.70 As stated before they showed the accuracy of their model but by 
omitting the model coefficients, it is not transferable to other patient populations. In a different study 
by our group102 it was shown that the percentage decrease in SUVmean (ΔSUVmean) and glucose 
metabolic rate (MRglc, derived from 2-compartment kinetic analysis) are both able to distinguish 
subgroups with different median overall survival in 50 patients with stage IV CRC treated by various 
schedules of chemotherapy. Using a cut-off for ΔSUVmean of -20% distinguished subgroups with a 
median survival of 25 weeks from 15 weeks (p=0.009). Using a ΔMRglc cut-off of -65% distinguished 
subgroups with a median survival of 32 weeks from 18 weeks (p=0.021). These cut-offs were selected 
after analysis of a range of cut-off values. Small et al.103 show similar results using FDG-PET/CT to 
qualitatively monitor treatment of 54 patients with liver metastases by FOLFOX / FOLFIRI (folinic 
acid / 5FU / irinotecan) with or without bevacizumab. Univariate analysis showed the hazard ratio of 
PET/CT response (defined as absence or reduced uptake of FDG) during treatment was not 
significantly associated with overall survival (3.127, 95% confidence interval: 0.874-11.187), but was 
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significantly associated with disease-free survival (3.826, 95% confidence interval: 1.390-10.534). 
CT-response alone did predict overall survival (hazard ratio: 4.584, 95% confidence interval: 1.133-
18.536) and progression free survival (hazard ratio: 2.925, 95% confidence interval: 1.078-7.937). 
Results of all abovementioned studies are displayed in table 7. 
Thus, the degree of metabolic response during treatment appeared to correlated with both 
pathological response and survival. However, it is of concern that the test-retest reproducibility of the 
SUVmean using a semi-automatically delineation of the lesion (50% of maximum value) is limited. 
When comparing the SUVmean of 28 lung cancer patients determined on the same system setup on two 
consecutive days, Krak et al.104 found a standard deviation of the relative differences of both 
SUVmean’s of 11%. In 26 cancer patients in whom a FDG-PET was repeated within 1-5 days, the 
standard deviation of the relative differences of both SUVmean’s was 7%.105 These standard deviations 
are larger when using different setups (multicentre trials). This suggests that measured tumour 
responses of less than ~15%-20% (2 standard deviations) might be regarded as within the 
reproducibility limits of the method used and should thus be interpreted as no actual change in SUV. 
Therapy decisions on PET-response seem feasible. However, before use in routine daily 
practice future randomised controlled trials are necessary to prove its value. Optimal cut-offs are not 
only dependent on patient, treatment setting and cytostatic agent, but are dependent on follow-up 
timing and reproducibility limits of this technique.106,107 
 
Conclusions 
FDG-PET has limited added value in staging primary CRC. It has a convincing role in detection of 
local recurrence when conventional imaging fails to distinguish scar tissue from recurrent or residual 
tumour and can influence management decisions in about 38%-82% of patients with unexplained rise 
in CEA. During pre-surgical restaging of local recurrence or metastases it may provide relevant 
information by detecting additional disease that renders laparotomy futile. The use of concomitant 
chemotherapy should be taken into account since it lowers sensitivity of PET. 
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Based on baseline FDG-PET, patients with recurrent or metastasised CRC treated by 
chemotherapy or surgical resection can be stratified in different subgroups based on prognosis or 
predicted therapy effect. This risk assessment might be used for individualised treatment assignment. 
The first studies that use this PET-based stratification for survival to select patients for different 
treatment schedules are currently being undertaken. 
The relation between FDG-PET response to preoperative neoadjuvant (chemo)radiotherapy in 
rectal cancer, seems well-related to both histopathology and survival. The exact clinical significance of 
PET-based response evaluation for this group of patients remains to be investigated. Unfortunately, 
early response prediction of radiotherapy seems less feasible since the combined effects of stunning, 
proliferation and inflammation may cause incorrect FDG-PET findings. In assessment of local ablative 
treatment of liver metastases FDG-PET seems suitable. The high predictive ability of negative FDG-
PET provides evidence that it can be used to assess radicality of tumour ablation. On the other hand, a 
positive FDG-PET might point to intensification of follow-up or even additional treatment. In case of 
chemotherapy response evaluation in metastasised CRC, there is a clear relation the results of FDG-
PET early after start of treatment with pathological response and survival. This could improve patient 
management by reducing morbidity, efforts and costs of ineffective treatment in non-responders. 
Moreover in an era where new and expensive drugs have limited morphologic effect, it may provide 
an alternative to anatomy-based assessment of response. However, it appears impossible to give one 
single definition of metabolic response, since cut-off values depend on type of treatment, timing of 
evaluation and tumour type.  
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Figure 1: Forest plot of management changes with corresponding confidence intervals for staging of 
primary rectal (upper) and primary colorectal cancer (CRC) described in nine references. The size of 
the squares denotes the weight for calculation of the pooled average.  
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Figure 2 
Figure 2: Example of a male patient with a pT3N0M1 rectosigmoid carcinoma treated by rectosigmoid 
resection in combination with chemotherapy for synchronous liver metastases. During follow-up with 
FDG-PET a local recurrence in the pelvis near the rectal stump was detected by PET/CT that was 
equivocal on CT.  
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Figure 3 
Figure 3: Forest plot of management changes with corresponding confidence intervals for 
preoperative restaging in colorectal liver metastases described in 25 references. The size of the squares 
denotes the weight for calculation of the pooled average.  
Page 34 of 42 
 
Figure 4 
Figure 4: Example of a male patient with a pT3N0M1rectosigmoid carcinoma treated by rectosigmoid 
resection in combination with chemotherapy. After an initially good response, resection of liver 
metastasis was performed. During follow-up with ultrasound, CT and FDG-PET a recurrence in the 
liver was detected by PET/CT which was not detected by ultrasound or CT alone.  






























Table 1: search strategy. MeSH: Medical Subject Heading, CT: X-ray computed tomography, PET: 
positron emission tomography, *truncation, †in EMBASE the corresponding subject heading is 
“Colorectal Cancer” 
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Table 2 
Table 2: Management changes and test characteristics in recurrent CRC by FDG-PET. CEA: carcinoembryonic antigen, CRC: colorectal carcinoma, CT: X-ray 
computed tomography, FDG: [18F]-fluoro-2’-deoxy-D-glucose, N/A: not applicable, PET: positron emission tomography, Se: sensitivity, Sp: specificity. *including 1 
patient in whom an incidental second tumour type was found, #test characteristics for extrahepatic metastases are based on detection of recurrent and metastatic CRC, 
†PET/CT compared to PET alone, §only locoregional lymph node metastases were included. 
First Author Year N Design Inclusion 
Unnecessary intervention 
Total (%) Test statistics PET versus CT 
Inconclusive CDW à  treatment  
Modifications to treatment plan    
Cancel other treatment for extensive disease  
Cancel surgery for extensive disease  
 Local recurrence Hepatic metastases 
Extra-hepatic 
metastases 
Cancel treatment for no disease  
Observation to start new treatment  
Disease free / benign  
Delbeke58 1997 52 Retrospective Suspected recurrence in CRC follow-up 6/52 
(histology or follow-up >12mo) 
2 2 9  4   17 (33%) N/A Se: 0.91 vs 0.81 Sp: 0.91 vs 0.60 
Se: 1.00 vs 0.74 
Sp: 0.40 vs 0.50 
Ruhlmann59 1997 59 Retrospective Suspected primary, screening follow-
up, suspected recurrence in CRC 
14/59 
(histology or suggested by CDW) 
2  2   2  6 (10%) N/A N/A N/A 
Imdahl60 2000 71 Prospective Suspected recurrence or metastases in 
CRC follow-up 
20/71 
(histology or suggested by CDW) 
7  9     16 (23%) Se: 0.92 vs 0.88 
Sp: 0.87 vs 0.89 
Se: 1.00 vs 0.87 
Sp: 0.98 vs 0.91 
Se: 0.94 vs 0.64 
Sp: 1.00 vs 0.98 
Whiteford61 2000 105 Retrospective Suspected recurrence or metastases 22/105 
(histology or follow-up >6mo) 
4 8 14    4 30 (29%) Se: 0.90 vs 0.71 
Sp: 0.92 vs 0.85 
Se: 0.89 vs 0.71 
Sp: 0.98 vs 0.92 
Se: 0.94 vs 0.67 
Sp: 0.98 vs 0.96 
Arulampalam62 2001 42 Prospective Suspected or confirmed recurrence 12/42 
(histology or follow-up) 
9  3  2*  2 16 (38%) Se: 1.00 vs 0.75 
Sp: 0.86 vs 1.00 
Se: 1.00 vs 0.45 
Sp: 1.00 vs 1.00 
Se: 0.93 vs 0.73# 
Sp: 0.58 vs 0.75# 
Desai63 2003 42 Prospective Follow-up or preoperative staging with 
resectable disease on CT 
0/42 
(histology or follow-up) 
  17     17 (40%) N/A N/A N/A 
Even-Sapir26 2004 62 Retrospective Suspected recurrence/metastases or 
preoperative staging in rectal cancer 
19/62 
(histology or follow-up >6mo) 
13 8  5  3  29 (47%) Se: 0.96 vs 0.88† 
Sp: 0.89 vs 0.74† N/A N/A 
Nakamoto64 2007 63 Prospective Suspected recurrence or screening 
follow-up PET/CT 
27/63 
(histology or follow-up >6mo) 
20 3  1 1  25 (40%) Se: 0.89 vs 0.75 
Sp: 0.96 vs 0.81 




  4  6   10 (16%) N/A Se: 0.92 vs 1.00 Sp: 1.00 vs 0.98 
Se: 0.43 vs 0.89§ 
Sp: 0.95 vs 0.52§ 
Page 37 of 42 
 
Table 3 
First Author Year n Inclusion Therapy PET-parameters Outcome-parameter Favourable 
criteria 
Results Sign. 
Calvo69 2004 25 cT2-4Nx primary rectal 
cancer 
CRT (45-50.4Gy, 5FU/FA 
or tegafur) + resection 
SUVmax 3-year overall survival SUVmax≤6.0 92% vs 60% 0.04 
Dimitrakopoulou-
Strauss70 
2004 20 CRC metastases 2nd line FOLFOX SUVmean, k1-4, 
FD, Vb  
1-year overall survival SUVmean 
k1, k3, Vb & FD 
CCR: 67% 
CCR: 76%  
- 
de Geus-Oei71 2006 152 CRC metastases Resection or pyrimidine 
based chemotherapy 
SUVmean Median overall survival SUVmean ≤4.26 32mo vs 19mo 0.017 
Riedl72 2007 90 CRC liver metastases Resection SUVmax Median overall survival SUVmax<5 
SUVmax<7 
SUVmax<10 
>72mo vs 48mo 
>72mo vs 42mo 








CRC based on CDW 







1-year progression free survival No additional 
lesions detected 
60.5% vs 36.2% 
 




Table 3: Prognostic stratification by baseline FDG-PET.CCR: correct classification rate, CDW: conventional diagnostic workup, CRC: colorectal carcinoma, 
CRT: chemoradiotherapy, 5FU: 5-fluorouracil, FA: folinic acid, FD: fractal dimensions, FDG: [18F]-fluoro-2’-deoxy-D-glucose, FOLFOX: 
5FU/FA/oxaliplatin, k1-4: 2-compartment rate constants, PET: positron emission tomography, SUV: standardised uptake value, Vb: vascular fraction. 
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Table 4 





Oku73 2002 40 cT2-4 and/or N1-3 
primary rectal cancer 
Radiotherapy (50Gy) SUVmean CT shrinkage rate at 3-5 weeks  Correlation: -0.162 0.326 
Dimitrakopoulou-
Strauss74 
2003 28 CRC metastases 2nd line FOLFOX SUVmean Clinical response (WHO-
guidelines): PD, SD or PR 
SUVmean CCR: 96% (PD), 47% 
(SD) and 0% (PR) 
- 
Table 4: Therapy response prediction by baseline FDG-PET. CCR: correct classification rate, CR: complete remission, CRC: colorectal carcinoma, CT: X-ray 
computed tomography, 5FU: 5-fluorouracil, FA: folinic acid, FDG: [18F]-fluoro-2’-deoxy-D-glucose, FOLFOX: 5FU/FA/oxaliplatin, PD: progressive disease, 
PET: positron emission tomography, PR: partial remission, SD: stable disease, SUV: standardised uptake value, WHO: World Health Organization.  
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Table 5 
First Author Year n Inclusion Therapy PET-parameter Outcome-parameter Response criteria Results Sign. 
Engenhart77 1992 21 Unresectable 
recurrence 
40Gy photons, 14Gy neutrons ΔSUVmean at 8-9 
weeks 
Local control Complete response (SUVmean 
normalisation to background) 
PPV: 3/15 (0.20) 
NPV: 4/6 (0.67) 
 
Guillem93 2000 15 cT3 and/or N1 Neoadjuvant CRT (50.4Gy, 
5FU/FA) 
VRS, ΔSUVmean, 
δTLG at 5wks 
Histological response at 4-6wks Any decrease PPV: 15/15 (1.00) 
NPV: 0/0 (n/a/) 
- 
Oku73 2002 40 cT2-4 and/or N1-3  Neoadjuvant radiotherapy (50Gy) SUVmean-ratio at 3-
5wks 
CT shrinkage rate at 3-5wks - Correlation -0.383 0.0140 
Amthauer84 2004 20 cT3/4M0 Neoadjuvant CRT (45Gy, 
5FU/FA) + RH 
ΔSUVmax at 2-
4wks 
Histological response at 6-8wks Histological CR/PR, 
ΔSUVmax>-36% 
PPV: 6/6 (1.00) 
NPV: 13/14 (0.93) 
<0.001 
Calvo69 2004 25 cT2-4Nx  Neoadjuvant CRT (45-50.4Gy, 
5FU/FA or tegafur) 
Absolute change in 
SUVmax at 4-5wks 
Histological response at 5-8wks Histological T-stage decrease Responders: -3.3 
Non-responders: -1.9 
0.03 
Guillem85 2004 15 cT3 and/or N1 Neoadjuvant CRT (50.4Gy, 
5FU/FA) 
ΔSUVmax, δTLG at 
5wks 
Median OS and DFS  ΔSUVmax,≥ -62.5% 
 
δTLG ≥ -69.5% 
Mean OS: >54wks vs ~39wks 
Mean DFS: >54wks vs ~26wks 
Mean OS: >54wks vs ~27wks 





Denecke78 2005 23 cT3/4M0 Neoadjuvant CRT (45Gy, 
5FU/FA) + RH 
ΔSUVmax at 2-
4wks 
ΔT-stage at 6-8wks Any T-stage decrease or >65% volume 
reduction 
ΔSUVmax < -36% 
PPV: 13/17 (0.76) 
NPV: 6/6 (1.00) 
0.002 




Histological response at 6-8wks Pathological complete response ΔSUVmax -74.5% vs -52.1% 0.24 
Capirci79 2006 88 cT3/4 and/or N1-3 M0 Neoadjuvant CRT (50-56Gy, 
5FU) 
VRS, (SUVmax) at 
7wks 
5-year OS and DFS VRS ≤ 1 (focal/diffuse) or SUVmax <1.4 5-yr OS: 91% vs 70% 
5-yr DFS: 81% vs 62% 
0.024 
0.003 
Cascini90 2006 33 cT3/4 and/or N1 Neoadjuvant CRT (45Gy, 
FOLFOX + raltitrexed) 
ΔSUVmean at 
12days 
Histological response at 8wks Histological response ≤ scattered residual 
cells 
ΔSUVmean ≥ -52% 
ΔSUVmean -63% vs -22% 
 
PPV: 13/13(1.00),  
NPV: 18/20 (0.90) 
<0.0001 
Kalff80 2006 34 cT3/4NxM0 Neoadjuvant CRT (50.4Gy, 
5FU/FA ±oxaliplatin/carboplatin) 
VRS at 3-4wks 3-year OS and DFS VRS: CR, PR or SD/PD 3-yr OS: 100%, 79%, 0% 
3-yr DFS: 100%, 47%, 0% 
<0.0001 
<0.0001 




Histological response at 8-
10wks 
Histological response ≤ scattered residual 
cells 
ΔSUVmax ≥ -66.2% 
ΔSUVmax -75.9% vs -46.9% 
 
PPV: 17/22 (0.77) 
NPV: 19/23 (0.89) 
0.0015 





Histological response at 8-
10wks 
Histological down-staging 
ΔSUVmax ≥ -70% 
ΔSUVmax -72% vs -44% 
PPV: 7/12 (0.58) 
NPV: 9/9 (1.00) 
<0.001 




Histological response Histological complete response (T0N0) Responders: -67% 
Non-responders: -55% 
0.08 
Kristiansen81 2008 30 cT3/4 Neoadjuvant CRT (60Gy, uracil, 
tegafur, FA) 
Visual response at 
7wks (PET/CT) 
Histological response at 8wks Complete histological response 
Negative PET on follow-up 
PPV: 10/12 (0.83) 
NPV: 6/18 (0.13) 
- 




















Rosenberg91 2008 29 uT3NxM0 Neoadjuvant CRT (45Gy, 5FU) ΔSUVmean at 
14days and at 
5wks 
Histological response at 10wks ΔSUVmean at 14days≥ -35% 
Grade 1 histological response 
ΔSUVmean at 14days≥ -57.7% 
Grade 1 histological response 
PPV: 7/12 (0.58) 
NPV: 14/17 (0.82) 
PPV: 7/11 (0.64) 
NPV: 15/18 (0.83) 
- 
Siegel89 2008 32 uT2N+ or uT3Nx Neoadjuvant short course CRT 
(25Gy, 5FU) 
ΔSUVmax at 9days Histological response at 2wks Histological down-staging ≤ predominant 
fibrotic changes (TRG2) 
ΔSUVmax ≥ -40% 
No correlation - 
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Histological response at 6-8wks TRG ≤ 2 -83.0% vs -59.4% 0.025 
Table 5: Radiotherapy and multimodality (neoadjuvant) therapy response evaluation in locally advanced rectal cancer by FDG-PET, (C)RT: 
(chemo)radiotherapy, CT: X-ray computed tomography, DFS: disease free survival, FA: folinic acid, FDG: [18F]-fluoro-2’-deoxy-D-glucose, FOLFOX: 
5FU/FA/oxaliplatin, 5FU: 5-fluorouracil, MRI: magnetic resonance imaging, NPV: negative predictive value (fraction of responder on PET that are a clinical 
responder), OS: overall survival, PD: progressive disease, PET: positron emission tomography, PPV: positive predictive value (fraction of non-responder on 
PET that are clinical non-responders), PR: partial remission, RH: radiofrequency hyperthermia, SD: stable disease, SUV: standardised uptake value, TLG: 
total lesion glycolysis, TRG: tumour regression grade, T-stage: TNM-classification tumour stage, VRS: visual response score. 
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Table 6 
First Author Year n Therapy PET-parameters Outcome-parameter Response criteria Results 
Langenhoff98 2002 22 CSA or RFA Visual interpretation within 3wks Histopathology, follow-up >9mo, CT PET-negative NPV:17/17 (1.00) 
PPV: 4/5 (0.80)  
Donckier99 2003 17 RFA Visual interpretation at 1wk  
 
Visual interpretation at 3mo 
Follow-up >3mo by CT PET-negative NPV: 7/13 (0.54) 
PPV: 4/4 (1.00) 
NPV: 6/8 (0.75) 
PPV: 8/8 (1.00) 
Joosten97 2005 43 CSA or RFA Visual interpretation within 3wks Follow-up >3mo by CT PET-negative NPV: 35/36 (0.97) 
PPV: 6/7 (0.86) 
Denecke49 2007 21 LITT Visual interpretation at suspected progression 
(MRI or CEA) 
SUVmax at suspected progression (MRI or CEA) 
Histopathology, follow-up >12mo by MRI PET-negative 
 
SUVmax≤4.2 
NPV: 24/25 (0.96) 
PPV: 28/29 (0.97) 
NPV: 23/24 (0.96) 
PPV: 28/30 (0.93) 
Table 6: Response evaluation for local ablative treatment for unresectable CRC liver metastases by FDG-PET. CEA: carcinoembryonic antigen, CRC: 
colorectal carcinoma, CSA: cryosurgical ablation, CT: X-ray computed tomography, FDG: [18F]-fluoro-2’-deoxy-D-glucose, LITT: LASER induced 
thermotherapy, MRI: magnetic resonance imaging, NPV: negative predictive value (fraction of patients with response on PET having clinical response), PET: 
positron emission tomography, PPV: positive predictive value (fraction of patients with no response on PET having no clinical response), RFA: 
radiofrequency ablation, SUV: standardised uptake value.  
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Table 7 
First Author Year n Inclusion Therapy PET-parameters Outcome-parameter Response criteria Results Sign. 
Findlay101 1996 18 CRC liver metastases 
≥3cm 
5FU±IFα ΔT:L at 4-5 weeks CT response (WHO 
guidelines) at 12wks  







2003 28 CRC metastases 2nd line FOLFOX SUVmean Clinical response 
(WHO-guidelines) 
Clinical response: PD, SD 
or PR 
CCR: 92% (PD) 57% 




2004 20 CRC metastases 2nd line FOLFOX SUVmean, k1-4, FD, Vb at 
3mo 
1-year overall survival SUVmean 




de Geus-Oei102 2008 50 CRC metastases Various schedules ΔSUVmean, ΔMRglc at 2mo Median overall survival ΔSUVmean ≥ -20% 
ΔMRglc ≥ -65% 
25wks vs 15wks 
32wks vs 18wks 
0.009 
0.021 
Small103 2008 40 CRC liver metastases Neoadjuvant FOLFOX / 
FOLFIRI ± bevacizumab 
Visual PET-CT response Overall survival 
Disease free survival 




Table 7: Chemotherapy response evaluation by FDG-PET for CRC metastases. CCR: correct classification rate, CR: complete remission, CRC: colorectal 
carcinoma, CT: X-ray computed tomography, FA: folinic acid, FD: fractal dimensions, 18F-FDG: [18F]-fluoro-2’-deoxy-D-glucose, FOLFIRI: 
5FU/FA/irinotecan, FOLFOX: 5FU/FA/oxaliplatin, 5FU: 5-fluorouracil, IFα: interferon-α, k1-4: 2-compartment rate constants, HR: hazard ratio, MRglc: 
glucose metabolic rate, PET: positron emission tomography, PD: progressive disease, PR: partial remission, SD: stable disease, SUV: standardised uptake 
value, T:L: tumour to normal liver ratio, Vb: vascular fraction, WHO: World Health Organization. 




